A novel micelle-encapsulated platinum(II) anticancer agent

Area of Science:

• Materials Science
• Nanotechnology
• Pharmacology

Background:

• Platinum(II) compounds are crucial in chemotherapy but face challenges with solubility and delivery.
• Developing effective drug delivery systems is essential to improve therapeutic efficacy and reduce side effects.
• Macromolecular micelles offer a promising platform for encapsulating hydrophobic drugs.

Purpose of the Study:

• To encapsulate a hydrophobic platinum(II) compound, cis-(cha)(2)Pt(NO(3))(2), within self-assembled amphiphilic cyclotriphosphazene micelles (CP750).
• To evaluate the pharmacokinetic, biodistribution, cellular uptake, cytotoxicity, and acute toxicity of the micelle-encapsulated platinum(II) compound.
• To assess the potential of this novel formulation as a preclinical cancer therapeutic.

Main Methods:

• Self-assembly of amphiphilic cyclotriphosphazene [NP(MPEG750)(GlyPheLeu)(2)Et](3) (CP750) into macromolecular micelles.
• Encapsulation of hydrophobic cis-(cha)(2)Pt(NO(3))(2) within the CP750 micelles.
• Pharmacokinetic studies in rats, including blood circulation time and systemic exposure (AUC).
• Biodistribution studies in Sprague-Dawley rats to determine tumor-to-tissue ratios.
• In vitro cellular uptake studies in human cervical (HeLa) and lung (A549) tumor cells.
• Cytotoxicity assays against various cancer cell lines, including drug-resistant stomach tumor cells (SNU638).
• Acute toxicity assessment by determining LD(50) values.

Main Results:

• The micelle-encapsulated platinum(II) compound demonstrated significantly prolonged blood circulation and higher systemic exposure (AUC=43.5 μgh/ml) compared to free carboplatin (AUC=4.32 μgh/ml).
• Excellent tumor-to-tissue ratios (4.03 at 2h, 4.67 at 24h) were observed in biodistribution studies.
• The micellar formulation showed over 6 times higher cellular uptake in HeLa and A549 cells compared to the free platinum compound.
• Remarkably high cytotoxicity was observed against stomach tumor cells (SNU638), which are typically resistant to chemotherapy.
• The micellar platinum(II) compound exhibited a higher LD(50) (90 mg/kg) than the free compound (70 mg/kg), indicating reduced acute toxicity.

Conclusions:

• Cyclotriphosphazene micelles effectively encapsulate hydrophobic platinum(II) compounds, improving their pharmacokinetic profiles.
• The micellar formulation enhances tumor targeting, cellular uptake, and exhibits potent cytotoxicity, particularly against drug-resistant cancer cells.
• The reduced acute toxicity suggests a favorable safety profile for the micellar platinum(II) compound.
• This encapsulated platinum(II) compound represents a promising candidate for further preclinical development as an anticancer agent.